Kineta publishes preclinical data on KVA12123

Kineta announced the peer-reviewed publication in Frontiers in Immunology of preclinical data highlighting the potential of KVA12123 as a new immunotherapy against poorly immunogenic tumors. The publication titled “A Highly Potent Anti-VISTA Antibody KVA12123 – A New Immune Checkpoint Inhibitor and a Promising Therapy Against Poorly Immunogenic Tumors”, reports on the development of KVA12123. Key results from the publication include: High affinity binding to VISTA through a unique epitope that is distinct from other clinical-stage anti-VISTA mAbs; High specificity against VISTA with no cross-reactivity against other members of the B7 family; Blockade of VISTA binding to all four of its respective ligands; Ability to reverse T cell suppression by myeloid-derived suppressor cells, one of the main drivers of immune suppression in the tumor microenvironment; Ability to induce T cell and NK-mediated monocyte activation; Strong single-agent antitumor activity in several syngeneic tumor models and enhanced efficacy in combination with anti-PD-1; On-target induction of cytokines/chemokines associated with VISTA blockade; Well tolerated in preclinical toxicology studies without antibody-dependent cellular cytotoxicity or induction of CRS-related cytokines.